Jubilant Pharmova Limited — Board Meeting, 29-07-2025: Outcome of Board Meeting

Jubilant Pharmova has announced a board meeting outcome where it approved the consolidated financial results for the quarter ending June 30, 2025. The company delivered solid operational growth, with Q1 revenue rising to ₹1,900.7 Cr, up from ₹1,731.7 Cr year-over-year. Profit before exceptional items also saw a healthy increase to ₹154.4 Cr, compared to ₹103.8 Cr in the same quarter last year. Investors should note last year's higher reported net profit included a significant one-time gain. Additionally, an internal transfer of the API business to a wholly-owned subsidiary was approved, a strategic move with no impact on the consolidated financials.